FDA Grants Approval for avelumab
First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
24-Mar-2017 -
Merck and Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved BAVENCIO® (avelumab) Injection 20 mg/mL, for intravenous use, for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (mMCC). This indication is approved ...
avelumab
cancer drugs
Merck
+3